Surge in Revlimid Sales Propels Celgene's Solid Second Quarter

Celgene Corp.'s first full quarter following its March acquisition of Pharmion Corp. proved to be a strong one, as the Summit, N.J.-based firm reported "record" sales for its flagship multiple myeloma drug Revlimid and posted higher-than-expected second-quarter earnings. (BioWorld Today)